Adoptive cellular therapy using chimeric antigen receptor (CAR) T cells has led to a
paradigm shift in the treatment of various hematologic malignancies. However, the broad …

Adoptive T cells immunotherapy, specifically chimeric antigen receptor T cells (CAR-T), has
shown promising therapeutic efficacy in the treatment of hematologic malignancies. As …

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …

CRISPR/Cas9 gene editing technology is characterized by high specificity and efficiency,
and has been applied to the treatment of human diseases, especially tumors involving …

Chimeric antigen receptor engineered T (CAR T) cell therapy has developed rapidly in
recent years, leading to profound developments in oncology, especially for hematologic …

Acute myeloid leukaemia (AML) is a fatal and refractory haematologic cancer that primarily
affects adults. It interferes with bone marrow cell proliferation. Patients have a 5 years …

Recently, CAR-T cell therapy in hematological malignancies has received extensive
attention. The objective of this study is to gain a comprehensive understanding of the current …

Simple Summary Despite intensive standard treatment, acute myeloid leukemia (AML)
continues to be associated with a poor prognosis due to treatment resistance and a high risk …

Introduction The clinical success of chimeric antigen receptor-modified T cells (CAR-T cells)
for hematological malignancies has not been reproduced for solid tumors, partly due to the …

World's population is elevating at an alarming rate thus, the rising demands of producing
crops with better adaptability to biotic and abiotic stresses, superior nutritional as well as …